modelMirogabalin
Extends from Pharmacolibrary.Drugs.ATC.N.N02BF03.
Information
| name: | Mirogabalin | |
| ATC code: | N02BF03 | route: | oral |
| compartments: | 1 | |
| dosage: | 15 | mg |
| volume of distribution: | 36.9 | L |
| clearance: | 7.1 | L/h |
| other parameters in model implementation | ||
Mirogabalin is an oral gabapentinoid derivative developed for the treatment of neuropathic pain, including diabetic peripheral neuropathic pain and postherpetic neuralgia. It is a selective ligand for the α2δ subunit of voltage-gated calcium channels. Mirogabalin is approved in Japan and several Asian countries for pain management.
Pharmacokinetics
Healthy adult volunteers, both male and female, after single oral dose administration.
References
Yin, OQ, et al., & Miller, R (2016). Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin. Journal of clinical pharmacology 56(2) 203–212. DOI:10.1002/jcph.584 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26138993
Toyama, K, et al., & Ishizuka, H (2023). Pharmacokinetics and Bioequivalence of Mirogabalin Orally Disintegrating Tablets and Conventional Tablets in Healthy Japanese Participants. Clinical pharmacology in drug development 12(10) 985–990. DOI:10.1002/cpdd.1292 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37312273
Kato, M, et al., & Ishizuka, H (2018). Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment. Journal of clinical pharmacology 58(1) 57–63. DOI:10.1002/jcph.974 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28834546
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)